Hematopoietic stem cell injection for expressing CD19 chimeric antigen receptor and preparation method thereof

By expressing CAR19 on hematopoietic stem cells, HSC-CAR19 cells are formed, and the recurrence and progression after CART treatment is solved. Through multi-directional differentiation and remodeling of the immune microenvironment, long-term immune surveillance and efficient lymphoma cell clearance are achieved, which improves the Treatment effects and survival rates.

CN118949018APending Publication Date: 2024-11-15THE FIRST AFFILIATED HOSPITAL OF NAVAL MEDICAL UNIVERSITY OF CHINESE PEOPLES LIBERATION ARMY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411012521.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

About 50% of existing patients have recurrence or progression after CART treatment, mainly due to the loss of target antigen, immunosuppression of the lymphoma microenvironment and short survival time of CART cells, resulting in incomplete clearance of lymphoma cells.

Method used

Through gene editing, chimeric antigen receptors (CAR19) targeting CD19 are expressed on hematopoietic stem cells, and HSC-CAR19 cells are formed and autologous transplanted. HSC-CAR19 differentiates in vivo to produce CART, CAR-NK, and CAR-M CAR-γδT and other cells, jointly kill lymphoma cells, and reshape the immune microenvironment through cytokines to achieve long-term immune surveillance.

Benefits of technology

It improves the lymphoma response rate, extends the patient's survival time, reduces the risk of recurrence, and combines the advantages of ASCT and CART to avoid increasing the burden of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949018A_ABST
    Figure CN118949018A_ABST
Patent Text Reader

Abstract

The invention belongs to but is not limited to the technical field of biomedicine, and discloses a hematopoietic stem cell injection for expressing a CD19 chimeric antigen receptor and a preparation method thereof, through a gene editing mode, CAR19 is expressed on hematopoietic stem cells, and HSC-CAR19 is formed. An autologous hematopoietic stem cell transplantation operation is carried out through HSC-CAR19 cells, and after HSC-CAR19 is colonized in vivo, the HSC-CAR19 has the following three advantages: 1) immune cells with anti-tumor activity, such as CART, CAR-NK, CAR-M and CAR-gamma delta T, are formed in vivo through multidirectional differentiation, and CD19 positive and negative lymphoma cells are jointly killed; 2) cell factors are secreted through various cells, the lymphoma microenvironment is remodeled, and the inhibition of the immune microenvironment on immunotherapy is reduced; and 3) immune surveillance is formed through long-term existence of the HSC-CAR19 in vivo, so that lymphoma recurrence is avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to but is not limited to the field of biomedical technology, and in particular relates to a hematopoietic stem cell injection expressing a CD19 chimeric antigen receptor and a preparation method thereof. Background Art

[0002] B-cell lymphoma is the most common subtype of non-Hodgkin's lymphoma, accounting for about 95% of non-Hodgkin's lymphoma. The first-line chemotherapy regimen for B-cell lymphoma includes CHOP (cyclophosphamide + doxorubicin + vincristine + prednisone), etc., or combined with radiotherapy, and the complete remission rate of patients is 50%-70%. Since the 1990s, with the advent of rituximab (CD20 antibody, R) and its combination with chemotherapy, the efficacy of B-cell lymphoma has been significantly improved. At present, the complete remission rate of the first-line R-CHOP treatment regimen for B-cell lymphoma is about 70%-80%. However, there are still 20%-50% of lymphoma patients who are insensitive to the first-line regimen, or relapse after remission. These patients are called relapsed / refractory B-cell lymphoma patients. According to the SCHOLAR-1 study, the median survival time of patients with relapsed / refractory diffuse large B-cell lymphoma is only 6.3 months, and the 1-year overall survival rate is only 28%. For patients with relapsed / refractory B-cell lymphoma, the standard salvage treatment is high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (ASCT). However, even with standard salvage treatment, the median survival time of patients is only 14.4 months. For patients who cannot receive ASCT, the prognosis is very poor, and clinical trials are their main treatment option.

[0003] The CD19 molecule is a protein molecule expressed on the surface of B cells. It is a component molecule of the B cell antigen receptor and belongs to the immunoglobulin superfamily. Its molecular weight is about 95kDa. It plays an important role in the differentiation and development of B cells. It is expressed almost throughout the entire process of B cell development. More than 95% of B cell hematological malignancies (B cell lymphoma and leukemia) express CD19, and other tissue cells rarely express CD19. Therefore, the CD19 molecule is an important target molecule for the treatment of B cell tumors. In recent years, cell immunotherapy and antibody targeted therapy targeting CD19 have achieved significant therapeutic effects in B cell lymphoma.

[0004] Chimeric antigen receptor T cell (CART) therapy is an emerging immunotherapy in recent years. Its main mechanism is to collect the patient's own T lymphocytes and express receptors targeting tumor antigens on the surface of T cells through genetic engineering. This receptor is the chimeric antigen receptor (CAR). CAR mainly includes extracellular antigen recognition fragments (single-chain variable fragment ScFv), hinge region, transmembrane region, and intracellular signal transmission region. The second-generation CAR is currently commonly used, that is, a co-stimulatory molecule (CD28, 4-1BB or ICOS) is connected in series in the intracellular signal transmission region. CAR can mediate T cells to recognize specific antigens on the surface of tumor cells. It can activate T cells without the assistance of MHC molecules. It can specifically and efficiently kill tumor cells by releasing granzymes, secreting cytokines, expressing death receptors, etc., without damaging normal tissues. Therefore, CART treatment is a highly specific and efficient immune cell treatment method.

[0005] CART therapy has achieved very significant results in B-cell lymphoma. So far, 7 CART products have been approved for the treatment of B-cell tumors at home and abroad, including Kymriah (Novartis), Yescarta (Gilead / Kate), Tecartus (Gilead / Kate), Breyanzi (Bristol-Myers Squibb / Junuo), Abecma (Bristol-Myers Squibb / Junuo) approved by the US Food and Drug Administration, and Akilencel Injection (Fosun Kate) and Rekioluncel Injection (WuXi Junuo) approved by the China Food and Drug Administration. The complete remission rate of CART treatment for relapsed / refractory B-cell lymphoma is 50%-90%, and the long-term survival is 43%. ZUMA-7 and TRANSFORM are two Phase III completely randomized controlled clinical studies comparing CAR19T treatment and standard treatment. The results showed that CAR19T is more effective than standard salvage treatment. Therefore, the two CART products (Axi-cel and Liso-cel) are recommended by the NCCN guidelines as second-line treatment options for patients with primary refractory large B-cell lymphoma and relapse within 12 months.

[0006] The main adverse reactions of CART therapy include cytokine release syndrome (CRS), immune effector cell therapy-associated neurotoxicity (ICANS), B cell deficiency, and the relatively rare hemophagocytic syndrome (HLH). The occurrence of CRS, ICANS and HLH is mainly due to the release of cytokines by CART cell activation, and is mainly treated with IL-6 receptor antagonists (tocilizumab) or glucocorticoids. B cell deficiency is mainly due to normal B cell damage caused by CART-specific killing of B cells, which is mainly treated by supplementing immunoglobulins to enhance immunity and reduce opportunistic infections.

[0007] In addition to T cells, other immune cells, such as CAR, can also be used as carrier cells for CAR. Studies have shown that CAR-macrophages (CAR-M), CAR-NK cells, CAR-DC cells, and CAR-γδT cells all have tumor-killing effects, and each has its own advantages. CAR-M can infiltrate into lymphoma, CAR-NK can recognize cells that are negative for target antigens, and CAR-DC cells and CAR-γδT cells, in addition to their tumor-killing activity, can also present tumor antigens and activate immune cells in the tumor to kill tumor cells. At present, these immunotherapies are still in the preclinical or clinical research stage.

[0008] The main problem with CART therapy is that nearly 50% of patients experience relapse or progression after CART treatment. The main mechanisms of relapse after CART treatment are: (1) loss of target antigen. B-cell lymphoma is a heterogeneous tumor. Some lymphoma cells do not express or lowly express CD19, thereby escaping the immune system, which is an important cause of relapse after CART treatment. (2) The lymphoma microenvironment is complex and immunosuppressive, inhibiting the function of CART. B-cell lymphoma is similar to solid tumors and has a complex immunosuppressive microenvironment. Regulatory T cells (Treg), myeloid-derived suppressor cells (MDSC), transforming growth factor β (TGF-β), etc. in the microenvironment inhibit the function of CART cells, resulting in the inability of CART cells to eliminate lymphoma cells. (3) CART has a short survival time in vivo. The survival time of CART cells in vivo is negatively correlated with the relapse rate of the disease. Due to the low proliferation rate and short survival time of CART cells in vivo, lymphoma clearance is not complete, and some patients relapse.

[0009] Prior art treatment methods:

[0010] First, CART therapy

[0011] The CART treatment process mainly includes autologous T cell collection, CART preparation, lymphocyte clearance pretreatment, and CART cell infusion.

[0012] (1) T cell collection: peripheral blood mononuclear cells are obtained by peripheral blood lymphocyte apheresis;

[0013] (2) CART preparation: CD3+ T cells are sorted using magnetic beads. After T cells are activated using CD3 / CD28 magnetic beads, lentiviral vectors carrying targeted CARs are transferred into T cells to obtain CART. CART cells are amplified to obtain the target number of CART cells.

[0014] (3) Lymphatic pretreatment: usually FC regimen (fludarabine, cyclophosphamide)

[0015] (4) CART cell transfusion: The CART cell transfusion dose is generally 2×106 / kg or so.

[0016] Second, ASCT treatment

[0017] The ASCT treatment process mainly includes autologous hematopoietic stem cell (HSC) mobilization and collection, high-dose chemotherapy pretreatment and autologous hematopoietic stem cell infusion.

[0018] (1) Mobilization and collection of autologous HSCs: cytokines are used to mobilize bone marrow HSCs into peripheral blood, and peripheral blood HSCs are obtained by peripheral blood lymphocyte apheresis. The obtained HSCs are frozen at below -80°C;

[0019] (2) High-dose chemotherapy pretreatment: The main pretreatment regimens currently include BEAM (carmustine, etoposide, cytarabine, melphalan) regimen and CEAC regimen (semustine, etoposide, cytarabine, cyclophosphamide), etc. The main purpose is to eliminate lymphoma cells through high-dose chemotherapy;

[0020] (3) Autologous HSC transfusion: The frozen HSCs are quickly rewarmed in a 37°C water bath and the revived autologous HSCs are transfused through the central vein.

[0021] Disadvantages of existing treatment methods:

[0022] First, the shortcomings of CART therapy: (1) CART cells are difficult to infiltrate into lymphoma. For lymphomas with large tumor volumes, CART cannot completely eliminate lymphoma cells; (2) CART cells have a short proliferation and survival time in the body and cannot achieve immune surveillance, leading to lymphoma recurrence; (3) The lymphoma microenvironment inhibits CART cells, resulting in impaired CART cell function, low remission rate, and poor efficacy.

[0023] Second, the disadvantages of ASCT treatment: After autologous ASCT, the immune cells differentiated from HSC do not have anti-lymphoma function. Its therapeutic effect on lymphoma is similar to that of high-dose chemotherapy. Despite ASCT treatment, the remission rate of relapsed / refractory B-cell lymphoma is still very low and the recurrence rate is very high. Summary of the invention

[0024] In view of the problems existing in the prior art, the present invention provides the preparation of hematopoietic stem cells expressing CD19 chimeric antigen receptor (HSC-CAR19) and their application in the treatment of B cell lymphoma.

[0025] The present invention is achieved by providing a hematopoietic stem cell injection expressing a chimeric antigen receptor (CAR19) targeting CD19, wherein the injection comprises CAR targeting CD19 expressed on hematopoietic stem cells by gene editing to form HSC-CAR19 cells for the treatment of B cell lymphoma.

[0026] Furthermore, the HSC-CAR19 cells in the injection are capable of undergoing autologous hematopoietic stem cell transplantation, and colonize in the body, persist and express CAR.

[0027] Furthermore, the HSC-CAR19 cells in the injection have multidirectional differentiation capabilities in vivo, and can form a variety of immune cells with anti-tumor activity, such as CART, CAR-NK, CAR-M and CAR-γδT targeting CD19, and kill lymphoma cells through the combined action of multiple cells and secrete cytokines.

[0028] Furthermore, the HSC-CAR19 cells in the injection have the ability to self-renew in the body, and can continue to exist in the body and maintain the number and activity of CAR-expressing immune cells.

[0029] Furthermore, the injection is a drug used to treat B-cell lymphoma. By injecting HSC-CAR19 cells into the patient's body, the long-term presence of immune cells expressing CAR19 in the body is achieved, thereby achieving the effect of treating B-cell lymphoma.

[0030] Furthermore, the preparation process of the injection includes the steps of HSC collection, gene editing, amplification, purification and formulation, and finally an injection that meets the drug quality standards is produced for the clinical treatment of B-cell lymphoma.

[0031] The present invention also provides a method for preparing a CD19-targeted chimeric antigen receptor cell injection, comprising the following steps:

[0032] (1) HSC sorting: CE regimen (cyclophosphamide + etoposide) chemotherapy + human granulocyte stimulating factor regimen is used to mobilize bone marrow HSC into peripheral blood, collect peripheral blood HSC, and go through a series of separation and purification steps to obtain pure HSC cells using magnetic bead sorting method;

[0033] (2) HSC cell transduction: Purified HSC cells are cultured and transduced with lentivirus to make HSC cells express CAR19 to form HSC-CAR19 cells;

[0034] (3) HSC-CAR19 cell medium replacement: The transduced HSC-CAR19 cells were treated with medium replacement and cultured continuously;

[0035] (4) Harvesting and freezing of HSC-CAR19 preparations: The cultured HSC-CAR19 cells were harvested, washed multiple times to remove the supernatant, and then the cells were counted. Finally, they were resuspended in freezing solution according to a specific density, divided into freezing bags, cooled by a programmed cooling device, and then transferred to a liquid nitrogen tank for freezing.

[0036] Furthermore, in the HSC sorting step, it specifically includes: mobilizing bone marrow HSC into peripheral blood through CE regimen (cyclophosphamide + etoposide) chemotherapy and human granulocyte stimulating factor, collecting peripheral blood HSC, and through a series of centrifugation, separation, and purification steps, using magnetic bead sorting to obtain pure HSC cells.

[0037] Furthermore, in the steps of harvesting and freezing the HSC-CAR19 preparation, it specifically includes: harvesting the cultured HSC-CAR19 cells, washing them multiple times to remove the supernatant, then counting the cells, and finally resuspending them with freezing solution according to a specific density, packaging them into freezing bags, and transferring them to a liquid nitrogen tank for freezing after cooling them through a programmed cooling device.

[0038] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:

[0039] First, B-cell lymphoma is the most common lymphoma. Currently, 20-50% of lymphoma patients face the risk of relapse and progression after treatment. The main salvage treatments for relapsed / refractory B-cell lymphoma currently include ASCT and CART, but whether it is ASCT or CART treatment, the remission rate of relapsed / refractory B-cell lymphoma is not high, and the long-term survival rate is very low. To address this problem, researchers have tried to solve it through molecular targeted therapy, immunotherapy, antibody-drug conjugate therapy, etc., but the effect is not significant.

[0040] Relapsed / refractory B-cell lymphoma is the most urgent problem to be solved in the field of lymphoma treatment. This method forms HSC-CAR19 by expressing CAR (CAR19) targeting CD19 in HSC, and HSC-CAR19 is transplanted into the body. HSC-CAR19 exists in the body for a long time and differentiates to produce a variety of immune cells targeting CD19, such as CART, CAR-M, CAR-NK and CAR-γδT, etc., which can achieve the joint killing of lymphoma cells by multiple immune cells, secretion of cytokines to reshape the immune microenvironment, activation of immune cells in lymphoma to clear target antigen-negative cells, and long-term immune surveillance, so as to solve the problem of relapsed / refractory B-cell lymphoma with "one stone and four birds", and provide reference for the treatment of other solid tumors, with extremely high social value. The present invention has the advantages of both ASCT and CART in the treatment of patients with relapsed / refractory B-cell lymphoma, improves the efficacy, and does not increase the economic and treatment burden of patients. The present invention forms HSC-CAR19 by making HSC express CAR. Its main advantages include: (1) Through the multidirectional differentiation of HSC-CAR19 in vivo, CART, CAR-M, CAR-NK, CAR-DC and CAR-γδT cells targeting CD19 tumor antigens are produced, and multiple mechanisms are combined to completely eliminate lymphoma cells and improve the remission rate of lymphoma; (2) After activation, CAR-M, CAR-DC and CAR-γδT cells secrete cytokines such as IL-2, TNF-α and IFN-γ, reshape the lymphoma microenvironment, reduce immunosuppression, promote CART and CAR-NK functions, completely eliminate lymphoma cells, and reduce recurrence; (3) Through the self-renewal of HSC-CAR19 in vivo, immune cells expressing CAR can continue to exist in the body, thereby achieving immune surveillance and reducing lymphoma recurrence. The present invention may overcome the clinical problem of relapsed / refractory B-cell lymphoma and provide a reference for the treatment of solid tumors.

[0041] Second, the technical solution of the present invention fills the technical gap in the industry at home and abroad: constructing HSC expressing CAR19, transplanting it into the patient's body through HSC-CAR19, multi-directionally differentiating to produce immune cells targeting CD19 lymphoma antigens, jointly killing lymphoma cells, reshaping the lymphoma microenvironment and long-term immune surveillance, which will be beneficial to improving the efficacy of relapsed / refractory B-cell lymphoma. This treatment plan was proposed for the first time at home and abroad, filling the technical gap at home and abroad.

[0042] The technical solution of the present invention solves the technical problem that people have been eager to solve but have never succeeded: the efficacy of relapsed / refractory B-cell lymphoma is very poor, which is a clinical problem that needs to be solved urgently. This study uses gene editing, stem cell transplantation therapy and cellular immunotherapy to express CAR19 in HSC to form HSC-CAR19, and through HSC-CAR19 transplantation, differentiate and produce a variety of CAR-carrying immune cells in vivo, which can kill lymphoma cells by combining multiple mechanisms, reshape the immunosuppressive microenvironment, reduce the inhibition of immune cells, and achieve long-term immune surveillance through the long-term presence of HSC-CAR19 in the body. This technology is conducive to solving the problem of poor prognosis of relapsed / refractory B-cell lymphoma and has great social value. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 It is a process flow chart of HSC-CAR19 injection production provided by an embodiment of the present invention;

[0044] Figure 2 Schematic diagram of HSC sorting and purification provided by an embodiment of the present invention;

[0045] Figure 3 This is a schematic diagram of the transduction efficiency of the HSC-CAR19 test sample provided in an embodiment of the present invention;

[0046] Figure 4 This is a schematic diagram of CAR19 gene insertion site detection provided by an embodiment of the present invention;

[0047] Figure 5 This is a schematic diagram of the HSC-CAR19 colony formation experiment provided in an embodiment of the present invention;

[0048] Figure 6 This is a schematic diagram of the HSC-CAR19 tissue and organ morphology provided by an embodiment of the present invention;

[0049] Figure 7 This is a graph showing the therapeutic effect of an animal model provided by an embodiment of the present invention. DETAILED DESCRIPTION

[0050] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0051] The use of HSC-CAR19 provided in an embodiment of the present invention in the preparation of a drug for treating B-cell lymphoma, by gene editing, CAR19 is expressed on HSC to form HSC-CAR19.

[0052] The drug is a CD19-targeted chimeric antigen receptor cell injection.

[0053] Production process of targeted CD19 chimeric antigen receptor cell injection provided by embodiments of the present invention

[0054] (I) Cell preparation process flow chart

[0055] HSC cells were sorted from peripheral blood apheresis, cultured for 1 day, transduced with lentivirus, and HSC-CAR19 cells were cultured in culture medium for 1 day before harvesting and freezing the cell preparation. Figure 1 shown.

[0056] (II) Description of the cell preparation process

[0057] (1) HSC sorting

[0058] a. Mobilize bone marrow HSC into peripheral blood through CE regimen (cyclophosphamide + etoposide) chemotherapy + human granulocyte stimulating factor, collect peripheral blood stem cells through blood cell apheresis machine, and transport them to the laboratory through 2-8℃ cold chain;

[0059] b. Take the blood bag out of the refrigerator at 2-8℃ and let it stand at room temperature for about 20 minutes to return to room temperature.

[0060] c. In a biosafety cabinet, use a syringe to draw anticoagulated blood from the blood bag and transfer it to a 50 ml centrifuge tube.

[0061] d. Add normal saline to dilute the apheresis isolate.

[0062] e. Prepare lymphocyte separation solution according to the volume of blood collected, and perform separation according to the ratio of blood sample (after dilution): separation solution = 1:1.

[0063] f. Centrifuge horizontally at 700 g for 20 minutes at room temperature in a centrifuge.

[0064] g. After centrifugation, aspirate the white film layer and transfer it to a 50 mL centrifuge tube. Add 4-5 times the volume of sorting buffer and centrifuge at 500 g at room temperature for 10 minutes. Aspirate and discard the supernatant.

[0065] h. Add sorting buffer to make up to 50 ml and resuspend the pellet, take a sample and count it, and centrifuge the cell suspension at 500g for 10 minutes.

[0066] i. Aspirate and discard the supernatant. According to the cell counting results, 8 Add 300 μL sorting buffer, 100 μL complement blocking antibody and CD34+ magnetic beads to each cell, mix the liquid by blowing gently with a pipette, and incubate the mixed sample at 4°C for 30 minutes.

[0067] j. After incubation, add 10 mL of sorting buffer to the incubation liquid, mix by inverting, and centrifuge at 1000 rpm at room temperature for 5 min.

[0068] k. When centrifuging cells, place the magnetic column on the magnetic rack, place a waste liquid tank under the magnetic column, and add 3 mL of sorting buffer to rinse the magnetic column.

[0069] l. After cell centrifugation, 1×10 8 Add 500 μL of sorting buffer to each cell, resuspend the cells by blowing and then add them to the rinsed magnetic column. The cells labeled with CD34+ magnetic beads will be adsorbed to the magnetic column, otherwise they will flow out directly.

[0070] m. After the added cell suspension has completely flowed out, add 3 mL of sorting buffer to wash the magnetic column. After the sorting buffer has flowed out of the magnetic column, add 3 mL of sorting buffer again. Repeat this process for a total of 3 washes.

[0071] After the last wash, remove the magnetic column from the magnetic stand and place it in a new sterile 15 mL centrifuge tube. Add 5 mL of sorting buffer to the magnetic column and push the liquid into the 15 mL centrifuge tube as quickly as possible.

[0072] o. At this time, the sorting buffer in the 15 mL centrifuge tube contains relatively pure HSC cells. Count the purified cells on a counting plate. Centrifuge at room temperature at 1000 rpm for 5 minutes.

[0073] p. After centrifugation, discard the supernatant, add HSC cell culture medium, and plate the cells into a cell culture dish and wait for subsequent experiments.

[0074] (2) HSC cell transduction

[0075] a. Take out the culture flask containing HSC cells from the incubator and double-check the label information.

[0076] b. After the label information is correct, open the culture bottle cap in the biosafety cabinet, mix the cell suspension with a 10mL disposable pipette, and perform HSC cell viability and live cell density detection; calculate the total number of HSC live cells based on the results.

[0077] c. Calculate the volume of virus required to be added according to the multiplicity of infection (MOI) of 5, and mix the cell suspension and virus with a 10mL disposable pipette.

[0078] d. A label for this process is affixed to the surface of the cell culture dish, which contains: batch number, process name, process time, operation date and suspension volume.

[0079] e. Place the six-well plate in an incubator at 37°C and 5% carbon dioxide (CO2).

[0080] (3) HSC-CAR19 cell medium replacement

[0081] a. The staff disinfects the outer surface of the HSC complete culture medium and places it in a biosafety cabinet.

[0082] b. After disinfecting the operator's hands, open a small hole in the CO2 incubator and carefully take out the six-well plate containing the cell fluid. Two people review the process label information, observe with the naked eye whether the cell fluid is clear and transparent, and observe the state of the growing cells under a microscope.

[0083] c. After disinfecting the outer surface of the six-well plate, move it to a biosafety cabinet, open the six-well plate cover, use a 1000uL pipette to repeatedly pipette each well 5 to 10 times, mix thoroughly, transfer all to a 50mL centrifuge tube, and mix well.

[0084] d. Use a 200uL pipette to pipette 50uL of cell suspension from the 50mL centrifuge tube into a 1.5mL microcentrifuge tube, transfer it out of the biosafety cabinet, and perform cell viability and live cell density testing.

[0085] e. Place a 50 mL centrifuge tube in a centrifuge and centrifuge at 500 g for 10 min.

[0086] f. In a biosafety cabinet, unscrew the cap of a 50mL centrifuge tube, use a 10mL disposable pipette to aspirate and discard the supernatant, and gently tap the bottom of the centrifuge tube to remove the precipitate;

[0087] g. Add HSC complete culture medium, mix the cell suspension, and adjust the cell density to 0.5-1.0×10 6 cells / ml;

[0088] h. Transfer the cell suspension into a T25 culture bag for culture.

[0089] i. Place the cells in a 37°C, 5% CO2 incubator to continue.

[0090] (4) Harvesting and freezing of HSC-CAR19 preparations

[0091] a. Take out the cell culture bag from the incubator, wipe it with 75% alcohol, and disinfect it, then place it in the biosafety cabinet.

[0092] b. Take 20uL of cell suspension with a pipette and count the cells.

[0093] c. In a biosafety cabinet, dispense the cell suspension into 50 mL centrifuge tubes. The volume of cell suspension in each centrifuge tube should not exceed 40 mL. Place the centrifuge bottle in a centrifuge at room temperature and 500 g for 10 minutes.

[0094] d. After centrifugation, take out the centrifuge tube, clean and disinfect the outer surface with 75% alcohol, open the cap in the biosafety cabinet, and remove the cell supernatant. Pour the supernatant gently to prevent the cells from falling to the bottom of the centrifuge bottle.

[0095] e. Add 40 mL of 0.9% sodium chloride injection to each centrifuge tube and gently pipette to mix the cell suspension. Then place the centrifuge bottle in a centrifuge at 500g for 10 minutes.

[0096] f. After centrifugation, take out the centrifuge tube, clean and disinfect the outer surface with 75% alcohol, open the cap in the biosafety cabinet, and remove the cell supernatant. Pour the supernatant gently to prevent the cells from falling to the bottom of the centrifuge tube.

[0097] g. Add 40mL of 0.9% sodium chloride injection to each centrifuge tube and gently pipette to mix the cell suspension. Take 20uL of the cell suspension for counting. Then place the centrifuge bottle in a centrifuge and centrifuge at 500g for 10 minutes.

[0098] h. After centrifugation, take out the centrifuge tube, clean and disinfect the outer surface with 75% alcohol, open the cap in the biosafety cabinet, and remove the cell supernatant. Pour the supernatant gently to prevent the cells from falling to the bottom of the centrifuge bottle.

[0099] i. The cells in the centrifuge bottle were divided into 1 to 5 × 10 6 / ml density and resuspend with freezing solution. All cell suspensions are transferred to the same container and mixed thoroughly to ensure cell uniformity.

[0100] j. Immediately divide the thoroughly mixed cell solution into pre-cooled cryopreservation bags.

[0101] k. Place the cryopreservation bag in an iron box and place it on a cryopreservation rack, then place it in a program cooling instrument, select the cryopreservation program, open the valve of the liquid nitrogen tank, click Start, and click Start again to cool down after downloading the program. After the program is finished, transfer the cryopreserved cells to the gas phase liquid nitrogen tank to be released.

[0102] 2. HSC-CAR19 transplantation for relapsed / refractory B-cell lymphoma

[0103] (1) Chemotherapy pretreatment

[0104] On days -6 to -2 before HSC-CAR19 cell infusion (day 0), the subjects need to receive CEAC chemotherapy pretreatment in the laminar flow ward. The specific regimen is as follows:

[0105] Semustine (250mg / m2) d-6,

[0106] Etoposide (300 mg / m2) for 3 hours d-5 to d-2

[0107] Cytarabine (500 mg / m2) q12h d-5~d-2

[0108] Cyclophosphamide (1.2 g / m2) d-5 to d-2

[0109] (2) HSC-CAR19 transplantation

[0110] a. Before reinfusion of HSC-CAR19, 25 mg of promethazine hydrochloride was injected intramuscularly to prevent allergic reactions;

[0111] b. HSC-CAR19 frozen at -80℃ or below is reinfused into the patient through the central vein at a dose of 2-4×10 5 / kg

[0112] c. Monitor the patient's clinical response, blood routine, liver and kidney function, cytokines, peripheral immune cell ratio, etc. to assess adverse reactions, and evaluate the treatment effect through enhanced CT / MRI or PET-CT.

[0113] Relevant evidence of the technical effects achieved by the embodiments of the present invention.

[0114] 1. HSC-CAR19 in vitro research data

[0115] 1.1 Hematopoietic stem cell (HSC) isolation and CAR19 gene transduction

[0116] The proportion of CD34+ cells in HSC collected from peripheral blood of patients was 0.95%±0.3%. After positive sorting with CD34 magnetic beads, the proportion of CD34+ cells increased to 93.6%±4.5% ( Figure 2 ), magnetic bead sorting significantly improved the purity of HSC to meet the needs of subsequent experiments. The sorted HSCs were transduced with the CAR19 gene using a lentiviral vector carrying CAR19, and the CAR19 gene transduction efficiency was 59.2% ± 19.1% ( Figure 3 ). After gene transduction, HSCs were stained with trypan blue and examined under a microscope, and the cell viability was 89%. The LM-PCR method was used to detect the insertion site of the CAR19 gene. Compared with the normal genome, the CAR19 gene had no insertion preference for oncogenes and tumor suppressor genes ( Figure 4). The results of pathogenic microorganism detection showed that no pathogenic microorganisms grew in the HSC-CAR19 test sample formed by CAR19 lentiviral vector transduction.

[0117] Figure 1 :Production flow chart

[0118] Figure 2 :HSC was detected by flow cytometry by incubation with CD34-PE flow antibody. The proportion of CD34+HSC in peripheral blood apheresis was 0.95%±0.3%; after sorting, the proportion of CD34+HSC was 93.6%±4.5% (n=7). Magnetic bead sorting significantly improved the purity of CD34+HSC, which met the requirements of subsequent experiments.

[0119] Figure 3 : CAR19 gene transduction was performed with CAR19 lentiviral vector to form HSC-CAR19 cells, CD19-PE protein was added, and flow cytometry was used to detect the transduction efficiency of 59.2%±19.1% (n=7). WT: untransduced HSC cells, CD34-LV: HSC transduced with CAR19 lentivirus; unstain: blank control; ISO: isotype control; FMC63: CD19-PE fluorescent protein bound to FMC63 receptor. The control group was WT-HSC; the experimental group was HSC-CAR19.

[0120] Figure 4 : After transduction with CAR19 lentiviral gene, LM-PCR was used to detect the CAR19 gene insertion site (n=3). Compared with the background gene, there was no significant difference in the expression of oncogenes and tumor suppressor genes after CAR19 lentiviral transduction. OCG: oncogene, TSG: tumor suppressor gene

[0121] 1.2 HSC-CAR19 colony formation assay

[0122] After HSC-CAR19 and WT-HSC were cultured in methylcellulose semi-solid medium for 10 days, the colony formation status and number were observed under a microscope. The results showed that there was no significant difference in the morphology and number of cell colonies between HSC-CAR19 and WT-HSC ( Figure 5 ). This indicates that CAR19 lentiviral gene transduction does not affect HSC proliferation and differentiation.

[0123] Figure 5: After HSC-CAR19 and WT-HSC were cultured in methylcellulose semi-solid medium for 10 days, the colony formation status was observed and counted under a microscope. CFU-E: erythroid colony-forming unit; BFU-E: blast-forming unit; CFU-GM: granulocyte-macrophage forming unit; CFU-GEMM: granulocyte-erythroid-macrophage-megakaryocyte colony-forming unit.

[0124] 2. HSC-CAR19 Animal Experiment Data

[0125]

[0126]

[0127] 1. Safety: HE staining of important tissues and organs showed that there was no significant difference in the morphology of heart, liver, spleen, lung, and kidney between the WT-HSC group and the HSC-CAR19 group, indicating that the treatment had no obvious toxic and side effects on normal tissues and organs ( Figure 6 ).

[0128] Figure 6 : HE staining images of important tissues and organs of mice in the HSC-WT and HSC-CAR19 groups.

[0129] 2. Efficacy: C57 / BL6N (CD45.2) mice were randomly divided into 2 groups (WT-HSC control group and HSC-CAR19 experimental group) after myeloablation pretreatment with 12Gy Co60. Each mouse was infused with 1×10 6 WT-HSC or HSC-CAR19 cells. Pharmacodynamic results showed that the tumor volume and tumor fluorescence increase rate in the HSC-CAR19 group were lower than those in the control group (P = 0.038 and P = 0.013) ( Figure 7 There was no significant difference in body weight between the WT-HSC group and the HSC-CAR19 group ( Figure 7 The median survival time of mice in the WT-HSC group and the HSC-CAR19 group was 23 days and 28 days, respectively (P=0.0067). The overall survival time of mice in the HSC-CAR19 group was significantly longer than that in the WT-HSC group ( Figure 7 ).

[0130] Figure 7 .Figure of the mouse B-cell lymphoma model treated with HSC-CAR19. A. In vivo imaging of mice; B. Fluorescence intensity of mice; C. Changes in weight of mice; D. Changes in tumor volume of mice; E. Survival time of mice.

[0131] The prognosis of patients with relapsed / refractory B-cell lymphoma is extremely poor. Currently, commonly used salvage treatments include high-dose chemotherapy, autologous hematopoietic stem cell transplantation, and CART immune cell therapy. However, after high-dose chemotherapy and autologous hematopoietic stem cell transplantation, the long-term survival of patients is only 26%, and the long-term survival rate after CART immune cell therapy is 43%. The main mechanisms of relapse and progression after CART immune cell therapy are: 1. The heterogeneity of lymphoma cells. Some lymphoma cells do not express or low-express CD19 antigens, resulting in CART cells being unable to recognize these tumor cells; 2. The lymphoma immune microenvironment inhibits CART cell function. A large number of immune transplanted cells in the lymphoma microenvironment make it difficult for CART cells to infiltrate into the tumor and to eliminate lymphoma cells in the microenvironment; 3. CART cell exhaustion. CART cells have a short survival time in the body, resulting in incomplete elimination of lymphoma cells, leading to relapse and progression.

[0132] In view of the above mechanism, combined with the current treatment methods, CAR19 is expressed on hematopoietic stem cells (HSC) through gene editing to form HSC-CAR19. Autologous hematopoietic stem cell transplantation is performed through HSC-CAR19 cells. After HSC-CAR19 is implanted in the body, 1) through multidirectional differentiation, immune cells with anti-tumor activity such as CART, CAR-NK, CAR-M and CAR-γδT are formed in the body, and multiple cells are combined to kill lymphoma cells and secrete cytokines to reshape the lymphoma microenvironment, which is conducive to stimulating immune cells to kill tumor cells with low or weak expression of CD19; 2) after activation, CAR-M, CAR-DC and CAR-γδT secrete IL-2, TNF-α, IFN-γ and other cytokines, reshape the lymphoma microenvironment, reduce immunosuppression, and improve the efficiency of CART and CAR-NK in killing lymphoma; 3) through the long-term presence of HSC-CAR19 in the body, immune surveillance is formed to avoid lymphoma recurrence.

[0133] From the perspective of animal research, the efficacy of HSC-CAR19 is significantly better than that of autologous hematopoietic stem cell transplantation. This technology is expected to solve the clinical problems of poor efficacy and prognosis of relapsed / refractory B-cell lymphoma, and provide reference for the treatment of other solid tumors. It has great application prospects and social value.

[0134] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.

Claims

1. A hematopoietic stem cell injection expressing CD19 chimeric antigen receptor, characterized in that: The injection contains HSC-CAR19 cells that express CAR19 on hematopoietic stem cells through gene editing, and is used to prepare drugs for the treatment of B-cell lymphoma.

2. The hematopoietic stem cell injection expressing CD19 chimeric antigen receptor according to claim 1, characterized in that: The HSC-CAR19 cells in the injection are capable of undergoing autologous hematopoietic stem cell transplantation, colonizing in the body, persisting and expressing CAR.

3. The hematopoietic stem cell injection expressing CD19 chimeric antigen receptor according to claim 1, characterized in that: The HSC-CAR19 cells in the injection have multidirectional differentiation capabilities in the body and can form a variety of immune cells with anti-tumor activity, such as CART, CAR-NK, CAR-M and CAR-γδT. They kill lymphoma cells through the combined action of multiple cells and secrete cytokines.

4. The hematopoietic stem cell injection expressing CD19 chimeric antigen receptor according to claim 1, characterized in that: The HSC-CAR19 cells in the injection have the ability to self-renew in the body, and can continue to exist in the body and maintain the number and activity of CAR-expressing immune cells.

5. The hematopoietic stem cell injection expressing CD19 chimeric antigen receptor according to claim 1, characterized in that: The injection is a drug used to treat B-cell lymphoma. By injecting HSC-CAR19 cells into the patient's body, it enables the long-term presence of immune cells expressing CAR19 in the body, thereby achieving the effect of treating B-cell lymphoma.

6. The hematopoietic stem cell injection expressing CD19 chimeric antigen receptor according to any one of claims 1 to 5, characterized in that: The preparation process of the injection includes the steps of hematopoietic stem cell collection, gene editing, amplification, purification and formulation, and finally an injection that meets the drug quality standards is produced for the clinical treatment of B-cell lymphoma.

7. A method for preparing a CD19-targeted chimeric antigen receptor cell injection, characterized in that: The following steps are involved: (1) HSC sorting: CE chemotherapy + human granulocyte stimulating factor regimen is used to mobilize bone marrow HSC into peripheral blood, collect peripheral blood HSC, and go through a series of separation and purification steps to obtain pure HSC cells using magnetic bead sorting method; (2) HSC cell transduction: Purified HSC cells are cultured and transduced with lentivirus to make HSC cells express CAR19 to form HSC-CAR19 cells; (3) HSC-CAR19 cell medium replacement: The transduced HSC-CAR19 cells were treated with medium replacement and cultured continuously; (4) Harvesting and freezing of HSC-CAR19 preparations: The cultured HSC-CAR19 cells were harvested, washed multiple times to remove the supernatant, and then the cells were counted. Finally, they were resuspended in freezing solution according to a specific density, divided into freezing bags, cooled by a programmed cooling device, and then transferred to a liquid nitrogen tank for freezing.

8. The method for preparing the targeted CD19 chimeric antigen receptor cell injection according to claim 7, characterized in that: The HSC sorting step specifically includes: mobilizing bone marrow stem cells into the peripheral blood through CE chemotherapy + human granulocyte stimulating factor, collecting peripheral blood stem cells, and obtaining pure HSC cells through a series of centrifugation, separation, and purification steps using magnetic bead sorting.

9. The method for preparing the targeted CD19 chimeric antigen receptor cell injection according to claim 7, characterized in that: The HSC-CAR19 preparation harvesting and freezing steps specifically include: harvesting the cultured HSC-CAR19 cells, washing them multiple times to remove the supernatant, then counting the cells, and finally resuspending them with freezing solution according to a specific density, packaging them into freezing bags, and cooling them through a programmed cooling device before transferring them to a liquid nitrogen tank for freezing.